Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...

Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

On Friday, Amgen Inc (AMGN) stock saw a decline, ending the day at $283.61 which represents a decrease of $-12.32 or -4.16% from the prior close of $295.93. The stock opened at $291.5 and touched a ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

On November 13, 2024, Amgen filed a BPCIA complaint in the District Court for the Eastern District of North Carolina against Accord Biopharma, Inc.; Accord Healthcare, Inc.; and Intas Pharmaceuticals, ...

In the ongoing case of Carefirst of Maryland Inc. v. Johnson & Johnson, the plaintiffs successfully overcame a motion to ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...